Phil Eyler
Analyst · Barrington Research. Please go ahead
Thank you, Yijing. Good morning, everyone, and thank you for joining us today. In the second quarter, the global pandemic continued to create significant hardship and challenges worldwide. Our top priority has continued to be the health, safety and support of our global team members and the communities we serve. I’m proud of the team for their strong execution in the second quarter despite the unprecedented conditions created by the worldwide COVID-19 pandemic. Let me start by sharing some of the key highlights of the quarter on Slide 4. While our 44% decline in total product revenue reflects the challenges in the underlying markets, we were able to outperform in Automotive in each of the key markets that we serve based on IHS’s July data. Adjusting for our higher revenue exposure in North America and Europe, we outperformed the actual light vehicle production by approximately 700 basis points. In medical, we delivered double-digit revenue growth, both year-over-year and sequentially. On the award front, our customer business units secured approximately $300 million in automotive new business awards in the second quarter. More importantly, we had the highest win rate in company history in the second quarter, securing over 90% of our opportunities. Moving to the cost side. Our ongoing disciplined approach to managing expenses allowed us to reduce operating expense by 30% from a year ago. Importantly, we generated a 24% increase in cash flow from operations in the first half of 2020 versus the prior year period. Despite the challenging environment, our balance sheet remains strong with total liquidity of nearly $370 million at quarter end. Matteo will provide more details on our financial results in a few minutes. Now turning to the automotive highlights on Slide 5. I’m very proud to share that Gentherm was named a 2019 General Motors supplier of the year. This prestigious GM supplier of the year award is presented to the top 1% of GM supply base. It’s even more rare for a Tier 2 supplier to win this recognition. This is the first time that Gentherm has been recognized by GM for our work to deliver exceptional solutions and customer service globally. GM is one of our longest-standing customers and continues to be an exceptional partner in developing and adopting our new technologies. Winning the supplier of the year award with our largest customer is a testament to our commitment to deliver the highest level of quality and service. I want to thank the entire Gentherm team for their dedication and commitment to quality, innovation, safety and operational excellence. Also in the second quarter, we launched our automotive solutions on 30 different vehicles across 29 OEMs, including FCA, GM and Hyundai-Kia. We continued to see momentum for our CCS product, and we launched on the Acura MDX, Chevy Blazer and Chevy Bolt, the GMC Sierra and Chevy Silverado, the Hongqi HS7 in China as well as the Kia K5 and Kia Optima. On the technology front, we continue to make great progress on ClimateSense development projects. As I’ve discussed in the past, Gentherm has been in development with a major European OEM. Now I’m pleased to announce that this OEM, BMW, has decided to extend our partnership, and we’ve kicked off a second phase of the advanced development project. Lastly, I’m excited to share that Lear has introduced its newest solution in intelligent seating the INTU Thermal Comfort with Gentherm’s ClimateSense technology. Our collaboration with Lear addresses consumer preferences of today and tomorrow by combining Gentherm’s expertise in human thermophysiology with Lear’s strength as a leader of automotive seating and electronic systems. The partnership has resulted in an intuitive solution that delivers faster passenger comfort and automatically adjust based on occupant temperature preferences and profiles. The INTU Thermal Comfort with ClimateSense technology is the first market-ready solution developed from this collaboration. Now on to Slide 6, where you can see that in the second quarter, we secured approximately $300 million in new program awards across 11 different customers. While the pandemic significantly impacted our revenue performance in the second quarter, our award momentum was strong. In the second quarter, we won multiple CCS awards, including platform wins with Cadillac XT 5, Ford Mustang and Hyundai Genesis. Also, I’m very pleased to announce that we recently secured our largest single vehicle production Climate Control Seat award in the company’s history. Gentherm will be the exclusive climate-controlled seat technology supplier for the global BMW 5 series, which is produced both in Europe and China. Also, Gentherm continues to grow our business with our largest customer, General Motors. In the second quarter, we were able to further secure 10 new program awards for our climate-controlled seat business for both North America and China. This was a significant achievement to expand our strong position with General Motors. In addition, we received steering wheel heater awards across 5 OEMs including the CLAR platform on all BMW X Series Vehicles, Ford Bronco, Honda Pilot and Porsche Cayenne. I’m also very excited to share that we are growing our business with Toyota, winning seat heater awards for the Lexus Rx and Lexis NX as well as the Toyota Sequoia. Our extremely strong win rate in the quarter, coupled with increased activities with many of the OEM customers, demonstrates the continued momentum we have in automotive. Now let’s turn to Slide 7 for a discussion of our medical business. In the second quarter, we delivered record quarterly revenue growing over 18% year-over-year. The majority of the growth resulted from the increase in Blanketrol equipment and consumable shipments across the U.S. and Europe to support temperature management of COVID-19 patients to help improve outcomes. In addition, through the U.S. Food and Drug Administration Emergency Use Authorization, our Hemotherm Model 400CE dual reservoir blood cooler heater, can be used to treat patients with COVID-19. This authorization from the FDA opens the way for Gentherm to provide support to health care professionals in treating patients with severe symptoms of COVID-19. Thanks to the enormous effort of our team, we are able to have a positive impact for patients and health care workers during this pandemic. Summarizing on Slide 8. Our steadfast execution against our strategic plan to focus our growth, divest non-core businesses, realign our cost structure and bring innovative solutions to the market has helped to create a stronger business foundation from which we can address the challenges we’re facing today. And it’s the agility, flexibility and dedication of our entire global workforce that’s enabling us to successfully deliver on our commitments to our customers during these unprecedented times. While the COVID-19 pandemic will continue to create challenges and uncertainties in the near term, the momentum we are seeing in new awards, winning the coveted General Motors supplier of the year award, coupled with aggressive cost management and our strong balance sheet, all position us well to continue to deliver over the long term. With that, I’ll turn the call over to Matteo for a little more color on the financial results.